<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513490087</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513490087</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Meta-analysis</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Two nonsynonymous polymorphisms (F31I and V57I) of the <italic>STK15</italic> gene and breast cancer risk: A meta-analysis based on 5966 cases and 7609 controls</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Qin</surname><given-names>Kai</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513490087">1</xref>
<xref ref-type="aff" rid="aff2-0300060513490087">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Cheng</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513490087">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wu</surname><given-names>Xiaoting</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513490087">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513490087"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513490087"><label>1</label>Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China</aff>
<aff id="aff2-0300060513490087"><label>2</label>Department of Surgery, DuJiangYan People’s Hospital, DuJiangYan, Sichuan Province, China</aff>
<author-notes>
<corresp id="corresp1-0300060513490087">Professor Xiaoting Wu, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guo Xue Road, Chengdu 610041, Sichuan Province, China. Email: <email>nutritioner@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>956</fpage>
<lpage>963</lpage>
<history>
<date date-type="received"><day>30</day><month>3</month><year>2013</year></date>
<date date-type="accepted"><day>8</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec11-0300060513490087"><title>Objectives</title>
<p>This meta-analysis examined the relationship between two nonsynonymous polymorphisms (F31I and V57I) of the aurora kinase A (<italic>STK15</italic>) gene and breast cancer risk.</p>
</sec>
<sec id="sec12-0300060513490087"><title>Methods</title>
<p>A systematic search of the PubMed® and EMBASE™ databases was undertaken to identify case–control studies that investigated the relationship between <italic>STK15</italic> gene polymorphisms and breast cancer risk.</p>
</sec>
<sec id="sec13-0300060513490087"><title>Results</title>
<p>This meta-analysis included seven case–control studies (5966 breast cancer cases; 7609 controls). Combined results, based on all seven studies, showed that breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype. In a subgroup analysis by race, breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype in Asians and Caucasians. Combined results, based on four studies, suggested that the <italic>STK15</italic> V57I gene polymorphism was unlikely to be associated with breast cancer risk in either Asians or Caucasians.</p>
</sec>
<sec id="sec14-0300060513490087"><title>Conclusions</title>
<p>The present meta-analysis suggests that the <italic>STK15</italic> F31I polymorphism is a strong predisposing risk factor for breast cancer, but no significant association existed between the <italic>STK15</italic> V57I polymorphism and the risk of breast cancer.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Aurora kinase A (<italic>STK15</italic>) gene</kwd>
<kwd>gene polymorphism</kwd>
<kwd>breast cancer</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513490087" sec-type="intro"><title>Introduction</title>
<p>Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths among females, accounting for 23% of total cancer cases and 14% of cancer deaths, worldwide.<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref></sup> Breast cancer is now also the leading cause of cancer deaths among females in economically developing countries: a shift from the previous decade during which the most common cause of cancer deaths was cervical cancer.<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref></sup> The mechanism of breast carcinogenesis is still not fully understood, but breast cancers are generally considered to result from interactions between multiple environmental, dietary, hereditary, racial and socio-economic risk factors.<sup><xref ref-type="bibr" rid="bibr2-0300060513490087">2</xref></sup></p>
<p>Aurora kinase A, which is encoded by the <italic>STK15</italic> gene (also known as <italic>BTAK</italic>), is involved in cell-cycle regulation, in particular the passage from G<sub>2</sub> to M, through the formation of mitotic spindles.<sup><xref ref-type="bibr" rid="bibr3-0300060513490087">3</xref></sup> Due to this regulatory function, the <italic>STK15</italic> gene has been hypothesized to be a potential cancer susceptibility gene. <sup><xref ref-type="bibr" rid="bibr3-0300060513490087">3</xref></sup> The <italic>STK15</italic> gene is located on chromosome 20q13.2.<sup><xref ref-type="bibr" rid="bibr4-0300060513490087">4</xref></sup> Two nonsynonymous polymorphisms F31I (rs2273535) and V57I (rs1047972) have been identified in the <italic>STK15</italic> gene.<sup><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref></sup> Both polymorphisms are located within two conserved motifs in the N-terminal region of the <italic>STK15</italic> gene.<sup><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref>,<xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup> A thymine (T)/adenine (A) polymorphism located at nucleotide position 91 encodes a phenylalanine (Phe)-to-isoleucine (Ile) (F31I) substitution at amino acid position 31.<sup><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref>,<xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup> A guanine (G)/A polymorphism at nucleotide 169 encodes a valine (Val)-to-Ile (V57I) substitution at amino acid position 57.<sup><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref>,<xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup> <italic>STK15</italic> gene polymorphisms have been reported to be associated with cancers of uterine,<sup><xref ref-type="bibr" rid="bibr7-0300060513490087">7</xref></sup> lung,<sup><xref ref-type="bibr" rid="bibr8-0300060513490087">8</xref></sup> oesophageal and ovarian tissue.<sup><xref ref-type="bibr" rid="bibr9-0300060513490087">9</xref>,<xref ref-type="bibr" rid="bibr10-0300060513490087">10</xref></sup></p>
<p>Studies have been performed to clarify the association between these two polymorphisms (F31I and V57I) of the <italic>STK15</italic> gene and breast cancer risk,<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> but have reported conflicting results. The purpose of this current meta-analysis was to undertake a detailed investigation of the relationship between <italic>STK15</italic> gene polymorphisms F31I and V57I and breast cancer risk.</p>
</sec>
<sec id="sec2-0300060513490087" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0300060513490087"><title>Literature search strategy</title>
<p>A systematic search of articles listed in electronic databases (PubMed® and EMBASE™), published between January 1950 and December 2012, was conducted using the following key words: ‘Aurora*’ or ‘<italic>STK15</italic>’ or ‘<italic>BTAK</italic>*’, ‘breast cancer’ or ‘breast carcinoma’, ‘polymorphism’ or ‘allele’ or ‘genetic variant’. No language restriction was used. Reference lists of the selected papers were screened by hand for potentially relevant new articles. If necessary, the corresponding authors of retrieved articles were contacted to acquire additional information. Furthermore, if more than one paper was published with an identical author using the same case series, the report with the larger sample size was selected. The list of articles was reviewed independently by two authors (K.Q. and C.W.).</p>
</sec>
<sec id="sec4-0300060513490087"><title>Inclusion and exclusion criteria</title>
<p>The criteria employed to select studies for this systematic review were as follows: (i) independent epidemiological case–control studies (for humans only); (ii) a clear description of <italic>STK15</italic> polymorphism in breast cancer cases and controls. The exclusion criteria were: (i) not an original paper (e.g. review or letter); (ii) duplicate publications; (iii) no control subjects.</p>
</sec>
<sec id="sec5-0300060513490087"><title>Data extraction</title>
<p>Literature and eligible articles were searched by two authors (K.Q. and C.W.). The following data were extracted: the last name of the first author, publication year, country, study design, genotyping method, sample size and the results of the study. Methodological quality of the selected studies was independently assessed by two investigators (K.Q. and C.W.) using the nonrandomized study methodology quality assessment scale for nonrandomized trials.</p>
</sec>
<sec id="sec6-0300060513490087"><title>Statistical analyses</title>
<p>Statistical analyses were performed using Stata® software (version 11.0; Stata Corp., College Station, TX, USA). The Mantel–Haenszel method was used for fixed effects and the method of DerSimonian and Laird was used for random effects to estimate the pooled odds ratio (OR) and corresponding 95% confidence interval (CI). A fixed-effects method was used if the result of the <italic>Q</italic>-statistic test was not significant; otherwise, the pooled estimates and confidence intervals were calculated based on a random-effects model. Publication bias was assessed by visual inspection of funnel plots, the Begg’s rank correlation method and the Egger’s weighted regression method. Subgroup analyses were performed on the basis of race. A <italic>P</italic>-value &lt; 0.05 was considered statistically significant and all statistical tests were two sided.</p>
</sec>
</sec>
<sec id="sec7-0300060513490087" sec-type="results"><title>Results</title>
<p>The initial database search identified 168 publications. After screening the titles and abstracts, 146 articles were excluded (86 did not study polymorphisms, 44 were not case–control studies, and 16 were not conducted in humans), which left 22 articles for a full publication review. Of these, a further 15 articles were excluded (13 were not case–control studies and two did not report useable data), leaving seven studies that met the inclusion criteria and were included in this current meta-analysis.<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> These seven studies included 5966 breast cancer cases and 7609 control subjects:<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> four were population-based case–control studies;<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref>,<xref ref-type="bibr" rid="bibr12-0300060513490087">12</xref>,<xref ref-type="bibr" rid="bibr16-0300060513490087">16</xref>,<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> three were hospital-based case–control studies.<sup><xref ref-type="bibr" rid="bibr13-0300060513490087">13</xref><xref ref-type="bibr" rid="bibr14-0300060513490087"/>–<xref ref-type="bibr" rid="bibr15-0300060513490087">15</xref></sup> Studies were conducted in the USA, UK and China (<xref ref-type="table" rid="table1-0300060513490087">Table 1</xref>).
<table-wrap id="table1-0300060513490087" position="float"><label>Table 1.</label><caption><p>Principal characteristics of seven studies included in a meta-analysis to investigate the relationship between aurora kinase A (<italic>STK15</italic>) gene polymorphisms F31I and V57I and breast cancer risk<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup>.</p></caption>
<graphic alternate-form-of="table1-0300060513490087" xlink:href="10.1177_0300060513490087-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Study</th>
<th>Design</th>
<th>Study period</th>
<th>Population/ country</th>
<th>Genotyping method</th>
<th>Cases, <italic>n</italic></th>
<th>Controls, <italic>n</italic></th>
<th>Polymorphisms</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Dai et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr7-0300060513490087">7</xref></sup></td>
<td>PCC</td>
<td>1996–1998</td>
<td>Asians/China</td>
<td>PCR</td>
<td>1132</td>
<td>1222</td>
<td>F31I, V57I</td>
</tr>
<tr>
<td>Egan et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup></td>
<td>PCC</td>
<td>1998–1999</td>
<td>Caucasians/USA</td>
<td>PCR</td>
<td>941</td>
<td>830</td>
<td>F31I, V57I</td>
</tr>
<tr>
<td>Sun et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref></sup></td>
<td>HCC</td>
<td>1997–2002</td>
<td>Asians/China</td>
<td>PCR–RFLP</td>
<td>520</td>
<td>520</td>
<td>F31I</td>
</tr>
<tr>
<td>Ewart-Toland  et al. 2005<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr4-0300060513490087">4</xref></sup></td>
<td>HCC</td>
<td>NR</td>
<td>Caucasians/USA</td>
<td>PCR–RFLP</td>
<td>898</td>
<td>448</td>
<td>F31I</td>
</tr>
<tr>
<td>Lo et al. 2005<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr3-0300060513490087">3</xref></sup></td>
<td>HCC</td>
<td>2002–2003</td>
<td>Asians/China</td>
<td>PCR</td>
<td>709</td>
<td>1972</td>
<td>F31I, V57I</td>
</tr>
<tr>
<td>Cox et al. 2006<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr2-0300060513490087">2</xref></sup></td>
<td>PCC</td>
<td>1989–2000</td>
<td>Caucasians/USA</td>
<td>PCR</td>
<td>1259</td>
<td>1742</td>
<td>F31I, V57I</td>
</tr>
<tr>
<td>Fletcher  et al. 2006<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref></sup></td>
<td>PCC</td>
<td>NR</td>
<td>Caucasians/UK</td>
<td>PCR–RFLP</td>
<td>507</td>
<td>875</td>
<td>F31I</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513490087"><p>PCC, population-based case–control; PCR, polymerase chain reaction; HCC, hospital-based case–control; RFLP, restriction fragment length polymorphism; NR, data not reported.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Genotyping results for the seven studies that reported on the association between <italic>STK15</italic> F31I gene polymorphisms and breast cancer are presented in <xref ref-type="table" rid="table2-0300060513490087">Table 2</xref>.<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> Combined results (based on all seven studies) showed that breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype genotype (OR [recessive model] 1.18, 95% CI 1.07, 1.30; OR [codominant model] 1.23, 95% CI 1.07, 1.41) (<xref ref-type="table" rid="table3-0300060513490087">Table 3</xref>) (<xref ref-type="fig" rid="fig1-0300060513490087">Figure 1</xref>). In the subgroup analysis by race, breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype, not only in Asians (OR [recessive model] 1.16, 95% CI 1.05, 1.30; OR [codominant model] 1.21, 95% CI 1.01, 1.45) but also in Caucasians (OR [recessive model] 1.26, 95% CI 1.01, 1.56; OR [codominant model] 1.26, 95% CI 1.01, 1.57) (<xref ref-type="table" rid="table3-0300060513490087">Table 3</xref>). Statistical heterogeneity was found by using the <italic>Q-</italic> statistic (<italic>P</italic> = 0.003). Publication bias was not found by the Begg’s rank correlation method or Egger’s weighted regression method.
<fig id="fig1-0300060513490087" position="float"><label>Figure 1.</label><caption><p>Meta-analysis of the association between the aurora kinase A (<italic>STK15</italic>) F31I gene polymorphism and risk of breast cancer.<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> ID, identity; OR, odds ratio; CI, confidence interval.</p></caption><graphic xlink:href="10.1177_0300060513490087-fig1.tif"/>
</fig>
<table-wrap id="table2-0300060513490087" position="float"><label>Table 2.</label><caption><p>Genotype counts of the aurora kinase A (<italic>STK15</italic>) gene polymorphisms (F31I and V57I) reported by seven studies included in a meta-analysis to investigate the relationship between <italic>STK15</italic> gene polymorphisms and breast cancer risk<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup>.</p></caption>
<graphic alternate-form-of="table2-0300060513490087" xlink:href="10.1177_0300060513490087-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Study</th>
<th rowspan="2">Polymorphisms</th>
<th colspan="3">Genotypes of cases<sup><xref ref-type="table-fn" rid="table-fn3-0300060513490087">a</xref></sup></th>
<th colspan="3">Genotypes of controls<sup><xref ref-type="table-fn" rid="table-fn3-0300060513490087">a</xref></sup></th>
<th rowspan="2">HWE</th>
</tr>
<tr><th>XX</th>
<th>Xx</th>
<th>xx</th>
<th>XX</th>
<th>Xx</th>
<th>xx</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="2">Dai et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr7-0300060513490087">7</xref></sup></td>
<td>F31I</td>
<td>121</td>
<td>491</td>
<td>490</td>
<td>149</td>
<td>503</td>
<td>534</td>
<td>0.07</td>
</tr>
<tr>
<td>V57I</td>
<td>805</td>
<td>281</td>
<td>16</td>
<td>908</td>
<td>263</td>
<td>17</td>
<td>0.68</td>
</tr>
<tr>
<td rowspan="2">Egan et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup></td>
<td>F31I</td>
<td>559</td>
<td>331</td>
<td>50</td>
<td>516</td>
<td>283</td>
<td>31</td>
<td>0.31</td>
</tr>
<tr>
<td>V57I</td>
<td>637</td>
<td>245</td>
<td>23</td>
<td>542</td>
<td>225</td>
<td>21</td>
<td>0.68</td>
</tr>
<tr>
<td>Sun et al. 2004<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref></sup></td>
<td>F31I</td>
<td>50</td>
<td>214</td>
<td>256</td>
<td>66</td>
<td>262</td>
<td>192</td>
<td>0.11</td>
</tr>
<tr>
<td>Ewart-Toland et al. 2005<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr4-0300060513490087">4</xref></sup></td>
<td>F31I</td>
<td>533</td>
<td>303</td>
<td>62</td>
<td>279</td>
<td>148</td>
<td>21</td>
<td>0.81</td>
</tr>
<tr>
<td rowspan="2">Lo et al. 2005<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr3-0300060513490087">3</xref></sup></td>
<td>F31I</td>
<td>71</td>
<td>288</td>
<td>348</td>
<td>196</td>
<td>887</td>
<td>886</td>
<td>0.23</td>
</tr>
<tr>
<td>V57I</td>
<td>543</td>
<td>146</td>
<td>15</td>
<td>1506</td>
<td>414</td>
<td>30</td>
<td>0.80</td>
</tr>
<tr>
<td rowspan="2">Cox et al. 2006<sup><xref ref-type="bibr" rid="bibr1-0300060513490087">1</xref><xref ref-type="bibr" rid="bibr2-0300060513490087">2</xref></sup></td>
<td>F31I</td>
<td>774</td>
<td>401</td>
<td>66</td>
<td>1075</td>
<td>571</td>
<td>65</td>
<td>0.31</td>
</tr>
<tr>
<td>V57I</td>
<td>870</td>
<td>342</td>
<td>28</td>
<td>1215</td>
<td>462</td>
<td>47</td>
<td>0.70</td>
</tr>
<tr>
<td>Fletcher et al. 2006<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref></sup></td>
<td>F31I</td>
<td>335</td>
<td>154</td>
<td>18</td>
<td>547</td>
<td>280</td>
<td>48</td>
<td>0.13</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0300060513490087"><p>Data presented as the number of cases or control subjects; note that the exact number for each polymorphism is often less than the total number of cases or controls included in the studies.</p></fn>
<fn id="table-fn3-0300060513490087"><label>a</label><p>For the F31I polymorphism: XX, phenylalanine/phenylalanine; Xx, phenylalanine/isoleucine; xx, isoleucine/isoleucine; for the V57I polymorphism: XX, valine/valine; Xx,valine/isoleucine; xx, isoleucine/isoleucine.</p></fn>
<fn id="table-fn4-0300060513490087"><p>HWE, Hardy–Weinberg equilibrium.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0300060513490087" position="float"><label>Table 3.</label><caption><p>Meta-analysis of aurora kinase A (<italic>STK15</italic>) gene polymorphisms F31I and V57I, and breast cancer risk<sup><xref ref-type="bibr" rid="bibr11-0300060513490087">11</xref><xref ref-type="bibr" rid="bibr12-0300060513490087"/><xref ref-type="bibr" rid="bibr13-0300060513490087"/><xref ref-type="bibr" rid="bibr14-0300060513490087"/><xref ref-type="bibr" rid="bibr15-0300060513490087"/><xref ref-type="bibr" rid="bibr16-0300060513490087"/>–<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup>.</p></caption>
<graphic alternate-form-of="table3-0300060513490087" xlink:href="10.1177_0300060513490087-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Polymorphism</th>
<th>Studies, <italic>n</italic></th>
<th>OR (95% CI) Recessive model xx versus [Xx + XX]<sup><xref ref-type="table-fn" rid="table-fn5-0300060513490087">a</xref></sup></th>
<th>Statistical significance of OR</th>
<th>Statistical significance of heterogeneity</th>
<th>OR (95% CI) Codominant model xx versus XX<sup><xref ref-type="table-fn" rid="table-fn5-0300060513490087">a</xref></sup></th>
<th>Statistical significance of OR</th>
<th>Statistical significance of heterogeneity</th>
<th>OR (95% CI) Codominant model Xx versus XX<sup><xref ref-type="table-fn" rid="table-fn5-0300060513490087">a</xref></sup></th>
<th>Statistical significance of OR</th>
<th>Statistical significance of heterogeneity</th>
</tr></thead>
<tbody align="left">
<tr>
<td>F31I</td>
<td>7</td>
<td>1.18 (1.07, 1.30)</td>
<td><italic>P</italic> = 0.001</td>
<td><italic>P</italic> = 0.003</td>
<td>1.23 (1.07, 1.41)</td>
<td><italic>P</italic> = 0.004</td>
<td><italic>P</italic> = 0.06</td>
<td>1.02 (0.93, 1.11)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td> Asians</td>
<td>3</td>
<td>1.16 (1.05, 1.30)</td>
<td><italic>P</italic> = 0.006</td>
<td><italic>P</italic> = 0.002</td>
<td>1.21 (1.01, 1.45)</td>
<td><italic>P</italic> = 0.04</td>
<td>NS</td>
<td>1.06 (0.88, 1.27)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td> Caucasians</td>
<td>4</td>
<td>1.26 (1.01, 1.56)</td>
<td><italic>P</italic> = 0.04</td>
<td><italic>P</italic> = 0.07</td>
<td>1.26 (1.01, 1.57)</td>
<td><italic>P</italic> = 0.04</td>
<td>NS</td>
<td>1.00 (0.91, 1.11)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>V57I</td>
<td>4</td>
<td>0.98 (0.74, 1.32)</td>
<td>NS</td>
<td>NS</td>
<td>0.99 (0.74, 1.33)</td>
<td>NS</td>
<td>NS</td>
<td>1.04 (0.94, 1.14)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td> Asians</td>
<td>2</td>
<td>1.20 (0.75, 1.91)</td>
<td>NS</td>
<td>NS</td>
<td>1.22 (0.77, 1.96)</td>
<td>NS</td>
<td>NS</td>
<td>1.10 (0.95, 1.26)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td> Caucasians</td>
<td>2</td>
<td>0.87 (0.60, 1.26)</td>
<td>NS</td>
<td>NS</td>
<td>0.87 (0.60, 1.26)</td>
<td>NS</td>
<td>NS</td>
<td>0.99 (0.87, 1.13)</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0300060513490087"><label>a</label><p>For the F31I polymorphism: XX, phenylalanine/phenylalanine; Xx, phenylalanine/isoleucine; xx, isoleucine/isoleucine; for the V57I polymorphism: XX, valine/valine; Xx, valine/isoleucine; xx, isoleucine/isoleucine.</p></fn>
<fn id="table-fn6-0300060513490087"><p>OR, odds ratio; CI, confidence interval; NS, not statistically significant (<italic>P</italic> ≥ 0.05).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Four studies reported on the association between <italic>STK15</italic> V57I gene polymorphism and breast cancer (<xref ref-type="table" rid="table2-0300060513490087">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr12-0300060513490087">12</xref>,<xref ref-type="bibr" rid="bibr13-0300060513490087">13</xref>,<xref ref-type="bibr" rid="bibr16-0300060513490087">16</xref>,<xref ref-type="bibr" rid="bibr17-0300060513490087">17</xref></sup> Combined results, based on all four studies, suggested that the <italic>STK15</italic> V57I gene polymorphism was unlikely to be associated with breast cancer risk (<xref ref-type="table" rid="table3-0300060513490087">Table 3</xref>). In the subgroup analysis by race, results demonstrated that the <italic>STK15</italic> V57I gene polymorphism was unlikely to be associated with breast cancer risk in either Asian or Caucasian subjects. Statistical heterogeneity was not found by using the <italic>Q-</italic>statistic.</p>
</sec>
<sec id="sec8-0300060513490087" sec-type="discussion"><title>Discussion</title>
<p>This current meta-analysis of seven studies involving 5966 breast cancer cases and 7609 control subjects was conducted in order to make a more precise estimation of the association between two nonsynonymous polymorphisms (F31I and V57I) of the <italic>STK15</italic> gene and breast cancer risk. Breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype, not only in Asians but also in Caucasians. However, no significant association existed between the <italic>STK15</italic> V57I polymorphism and the risk of breast cancer.</p>
<p>Studies investigating the association between genetic polymorphisms and breast cancer risk are being reported with rapidly increasing frequency. For example, a systematic review and pooled analysis of 10 studies, including 4644 cases and 5485 controls, suggested that rs1137101 and rs1137100 polymorphisms of the leptin receptor gene were significantly correlated with breast cancer risk; this study also found that the A allele of the rs1137101 variant and the G allele of the rs1137100 variant were low-penetrant risk factors for developing breast cancer.<sup><xref ref-type="bibr" rid="bibr18-0300060513490087">18</xref></sup> A meta-analysis of nine studies, involving 2597 cases and 2618 controls, suggested that the matrix metalloproteinase-2-1306 cytosine (C)/T polymorphism may contribute to breast cancer susceptibility.<sup><xref ref-type="bibr" rid="bibr19-0300060513490087">19</xref></sup> Another meta-analysis of 14 case–control studies (12 183 cases and 10 183 controls) suggested that the <italic>RAD51</italic> variant 135C homozygote was associated with elevated breast cancer risk among carriers of the breast cancer type 2 susceptibility protein gene mutation.<sup><xref ref-type="bibr" rid="bibr20-0300060513490087">20</xref></sup> A meta-analysis of 17 case–control studies (12 153 cases and 10 245 controls) suggested that the <italic>RAD51</italic> G135C polymorphism was a low-penetrant risk factor for developing breast cancer.<sup><xref ref-type="bibr" rid="bibr21-0300060513490087">21</xref></sup> The findings of a meta-analysis of 11 studies, including 5090 cases and 5214 controls, suggested that the xeroderma pigmentosum complementation group C PAT+/− polymorphism allele may be a low-penetrant risk factor for developing breast cancer.<sup><xref ref-type="bibr" rid="bibr22-0300060513490087">22</xref></sup> Rare alleles at the v-Ha-ras Harvey rat sarcoma viral oncogene homologue–variable number tandem repeats locus were identified as possibly contributing to breast cancer susceptibility in a meta-analysis of 13 studies (1926 cases and 2800 controls).<sup><xref ref-type="bibr" rid="bibr23-0300060513490087">23</xref></sup> A meta-analysis of seven studies (3177 cases and 4038 controls) suggested that the nicotinamide adenine dinucleotide phosphate hydrogen quinone oxidoreductase 1 proline187serine polymorphism may contribute to breast cancer development in Caucasians.<sup><xref ref-type="bibr" rid="bibr24-0300060513490087">24</xref></sup> A thymidylate synthase (<italic>TYMS</italic>) gene enhancer region polymorphism may increase susceptibility to breast cancer in the Caucasian population, and a <italic>TYMS</italic> gene 3′-untranslated region polymorphism may be a genetic determinant for developing breast cancer in the Asian population, as demonstrated by a meta-analysis of 10 eligible studies.<sup><xref ref-type="bibr" rid="bibr25-0300060513490087">25</xref></sup> A meta-analysis of 16 studies (involving 23 445 subjects) suggested that the sulphotransferase 1A1 codon 213 polymorphism may be associated with breast cancer susceptibility, based on data from hospital-based studies.<sup><xref ref-type="bibr" rid="bibr26-0300060513490087">26</xref></sup> A meta-analysis of 13 case–control studies (10 236 cases and 13 143 controls) indicated that the tumour necrosis factor-α 308 A allele may be an important protective factor for breast cancer in European individuals.<sup><xref ref-type="bibr" rid="bibr27-0300060513490087">27</xref></sup> Another meta-analysis of 30 case–control studies (15901 cases and 18 757 controls) suggested that the glutathione S-transferase pi gene Ile105Val polymorphism may increase susceptibility to breast cancer in the Asian population.<sup><xref ref-type="bibr" rid="bibr28-0300060513490087">28</xref></sup> A meta-analysis of seven case–control studies, including 26 015 cases and 33 962 controls, suggested that the mitogen-activated protein kinase kinase kinase 1 rs889312 C allele was a low-penetrant risk factor for developing breast cancer.<sup><xref ref-type="bibr" rid="bibr29-0300060513490087">29</xref></sup></p>
<p>The mechanism by which the <italic>STK15</italic> F31I polymorphism affects breast cancer risk is unclear. The F31I polymorphism is located within a conserved motif in the N-terminal region of the <italic>STK15</italic> gene.<sup><xref ref-type="bibr" rid="bibr5-0300060513490087">5</xref>,<xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup> This motif could be related to ubiquitin-dependent degradation in early G<sub>1</sub> that is dependent on the C-terminal degradation box domain; it might also serve as a localization domain to target the protein to the centrosome in a microtubule-dependent manner.<sup><xref ref-type="bibr" rid="bibr30-0300060513490087">30</xref>,<xref ref-type="bibr" rid="bibr31-0300060513490087">31</xref></sup> The Ile31 variant transforms rat1 cells more potently than the more common Phe31 variant.<sup><xref ref-type="bibr" rid="bibr6-0300060513490087">6</xref></sup> The <italic>STK15</italic> 31 Ile/Ile genotype has been associated with a significantly increased risk of uterine and ovarian cancer.<sup><xref ref-type="bibr" rid="bibr7-0300060513490087">7</xref>,<xref ref-type="bibr" rid="bibr10-0300060513490087">10</xref></sup></p>
<p>The present meta-analysis had several limitations that should be mentioned. First, relatively small sample sizes and significant heterogeneity were observed in the meta-analysis of <italic>STK15</italic> F31I gene polymorphisms and breast cancer. Secondly, because many environmental factors may affect breast cancer susceptibility, all of our current findings might be due to interactions between the genetic background and multiple environmental factors. Thirdly, because of the lack of individual patient data, it was not possible to perform an adjustment estimate. Finally, this meta-analysis pooled genetic association studies published between 2004 and 2006; all of these studies were conducted before the ‘Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement’ was published.<sup><xref ref-type="bibr" rid="bibr32-0300060513490087">32</xref></sup> Therefore, the studies included in this current meta-analysis did not fulfil all of the STROBE checklist items.</p>
<p>Despite these limitations, this current meta-analysis also had some advantages. First, a comprehensive search strategy based on computer-assisted and manual searching allowed all eligible studies to be included. Secondly, no publication bias was found, which would suggest a robust result.</p>
<p>In conclusion, the findings of this present meta-analysis suggest that the <italic>STK15</italic> F31I polymorphism is a strong predisposing risk factor for breast cancer. Furthermore, no significant association existed between the <italic>STK15</italic> V57I polymorphism and the risk of breast cancer.</p>
</sec>
</body>
<back>
<sec id="sec9-0300060513490087"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec10-0300060513490087"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513490087"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Global cancer statistics</article-title>. <source>CA Cancer J Clin</source> <year>2011</year>; <volume>61</volume>: <fpage>69</fpage>–<lpage>90</lpage>.</citation></ref>
<ref id="bibr2-0300060513490087"><label>2</label><citation citation-type="other"><comment>Nickels S, Truong T, Hein R, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. <italic>PLoS Genet</italic> 9: e1003284. doi:10.1371/journal.pgen.1003284</comment>.</citation></ref>
<ref id="bibr3-0300060513490087"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nigg</surname><given-names>EA</given-names></name></person-group>. <article-title>Centrosome aberrations: cause or consequence of cancer progression?</article-title> <source>Nat Rev Cancer</source> <year>2002</year>; <volume>2</volume>: <fpage>815</fpage>–<lpage>825</lpage>.</citation></ref>
<ref id="bibr4-0300060513490087"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Eki</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Assignment of STK6 to human chromosome 20q13.2–&gt;q13.3 and a pseudogene STK6P to 1q41–&gt;q42</article-title>. <source>Cytogenet Cell Genet</source> <year>1997</year>; <volume>79</volume>: <fpage>201</fpage>–<lpage>203</lpage>.</citation></ref>
<ref id="bibr5-0300060513490087"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>JR</given-names></name><name><surname>Anderson</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers</article-title>. <source>EMBO J</source> <year>1998</year>; <volume>17</volume>: <fpage>3052</fpage>–<lpage>3065</lpage>.</citation></ref>
<ref id="bibr6-0300060513490087"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ewart-Toland</surname><given-names>A</given-names></name><name><surname>Briassouli</surname><given-names>P</given-names></name><name><surname>de Koning</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>34</volume>: <fpage>403</fpage>–<lpage>412</lpage>.</citation></ref>
<ref id="bibr7-0300060513490087"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milam</surname><given-names>MR</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study</article-title>. <source>Gynecol Oncol</source> <year>2007</year>; <volume>107</volume>: <fpage>71</fpage>–<lpage>74</lpage>.</citation></ref>
<ref id="bibr8-0300060513490087"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians</article-title>. <source>Carcinogenesis</source> <year>2007</year>; <volume>28</volume>: <fpage>350</fpage>–<lpage>355</lpage>.</citation></ref>
<ref id="bibr9-0300060513490087"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>MT</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Conroy</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk</article-title>. <source>Cancer Res</source> <year>2005</year>; <volume>65</volume>: <fpage>3548</fpage>–<lpage>3554</lpage>.</citation></ref>
<ref id="bibr10-0300060513490087"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dicioccio</surname><given-names>RA</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Waterfall</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>STK15 polymorphisms and association with risk of invasive ovarian cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <year>2004</year>; <volume>13</volume>: <fpage>1589</fpage>–<lpage>1594</lpage>.</citation></ref>
<ref id="bibr11-0300060513490087"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk</article-title>. <source>J Natl Cancer Inst</source> <year>2006</year>; <volume>98</volume>: <fpage>1014</fpage>–<lpage>1018</lpage>.</citation></ref>
<ref id="bibr12-0300060513490087"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group>. <article-title>Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States)</article-title>. <source>Cancer Causes Control</source> <year>2006</year>; <volume>17</volume>: <fpage>81</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr13-0300060513490087"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YL</given-names></name><name><surname>Yu</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK</article-title>. <source>Int J Cancer</source> <year>2005</year>; <volume>115</volume>: <fpage>276</fpage>–<lpage>283</lpage>.</citation></ref>
<ref id="bibr14-0300060513490087"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ewart-Toland</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><etal/></person-group>. <article-title>Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types</article-title>. <source>Carcinogenesis</source> <year>2005</year>; <volume>26</volume>: <fpage>1368</fpage>–<lpage>1373</lpage>.</citation></ref>
<ref id="bibr15-0300060513490087"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma</article-title>. <source>Carcinogenesis</source> <year>2004</year>; <volume>25</volume>: <fpage>2225</fpage>–<lpage>2230</lpage>.</citation></ref>
<ref id="bibr16-0300060513490087"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>KM</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Ambrosone</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>STK15 polymorphism and breast cancer risk in a population-based study</article-title>. <source>Carcinogenesis</source> <year>2004</year>; <volume>25</volume>: <fpage>2149</fpage>–<lpage>2153</lpage>.</citation></ref>
<ref id="bibr17-0300060513490087"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>QY</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><etal/></person-group>. <article-title>Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <year>2004</year>; <volume>13</volume>: <fpage>2065</fpage>–<lpage>2070</lpage>.</citation></ref>
<ref id="bibr18-0300060513490087"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LQ</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The association between polymorphisms in the leptin receptor gene and risk of breast cancer: a systematic review and pooled analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2012</year>; <volume>136</volume>: <fpage>231</fpage>–<lpage>239</lpage>.</citation></ref>
<ref id="bibr19-0300060513490087"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>LF</given-names></name><name><surname>Lv</surname><given-names>GQ</given-names></name><etal/></person-group>. <article-title>Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>127</volume>: <fpage>813</fpage>–<lpage>818</lpage>.</citation></ref>
<ref id="bibr20-0300060513490087"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>GW</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>XD</given-names></name><etal/></person-group>. <article-title>RAD51 135G&gt;C polymorphism and breast cancer risk: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>125</volume>: <fpage>529</fpage>–<lpage>535</lpage>.</citation></ref>
<ref id="bibr21-0300060513490087"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>125</volume>: <fpage>157</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr22-0300060513490087"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Cong</surname><given-names>XF</given-names></name><name><surname>Cai</surname><given-names>WH</given-names></name><etal/></person-group>. <article-title>Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>128</volume>: <fpage>811</fpage>–<lpage>815</lpage>.</citation></ref>
<ref id="bibr23-0300060513490087"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lv</surname><given-names>GQ</given-names></name><name><surname>Yu</surname><given-names>XM</given-names></name><etal/></person-group>. <article-title>Current evidence on the relationship between HRAS1 polymorphism and breast cancer risk: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>128</volume>: <fpage>467</fpage>–<lpage>472</lpage>.</citation></ref>
<ref id="bibr24-0300060513490087"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>125</volume>: <fpage>467</fpage>–<lpage>472</lpage>.</citation></ref>
<ref id="bibr25-0300060513490087"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>128</volume>: <fpage>203</fpage>–<lpage>209</lpage>.</citation></ref>
<ref id="bibr26-0300060513490087"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>125</volume>: <fpage>215</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr27-0300060513490087"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>126</volume>: <fpage>763</fpage>–<lpage>770</lpage>.</citation></ref>
<ref id="bibr28-0300060513490087"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: a meta-analysis involving 34,658 subjects</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>125</volume>: <fpage>253</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr29-0300060513490087"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>PH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>126</volume>: <fpage>663</fpage>–<lpage>670</lpage>.</citation></ref>
<ref id="bibr30-0300060513490087"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfleger</surname><given-names>CM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group>. <article-title>The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1</article-title>. <source>Genes Dev</source> <year>2000</year>; <volume>14</volume>: <fpage>655</fpage>–<lpage>665</lpage>.</citation></ref>
<ref id="bibr31-0300060513490087"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dutertre</surname><given-names>S</given-names></name><name><surname>Descamps</surname><given-names>S</given-names></name><name><surname>Prigent</surname><given-names>C</given-names></name></person-group>. <article-title>On the role of aurora-A in centrosome function</article-title>. <source>Oncogene</source> <year>2002</year>; <volume>21</volume>: <fpage>6175</fpage>–<lpage>6183</lpage>.</citation></ref>
<ref id="bibr32-0300060513490087"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>J</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement</article-title>. <source>Hum Genet</source> <year>2009</year>; <volume>125</volume>: <fpage>131</fpage>–<lpage>151</lpage>.</citation></ref>
</ref-list>
</back>
</article>